June 20, 2017

Accenture Again Positioned as a Leader in IDC MarketScape on Life Science Drug Safety Services

NEW YORK ; June 20, 2017 – Accenture (NYSE: ACN) has been positioned as a “Leader” in IDC Health Insights’ recently published report, “IDC MarketScape: Worldwide Life Sciences Drug Safety Services 2017 Vendor Assessment.” 1 This is the second consecutive time Accenture has been named a Leader in the vendor assessment report, which is derived from qualitative and quantitative metrics as well as end-user feedback of drug safety service providers in the life sciences industry through the IDC MarketScape model. Click here for a link to the 2017 report.

The report notes that relative to other vendors discussed in this document and based on feedback from customer references, Accenture received high marks as an industry thought leader as well as a knowledgeable, unbiased, high-quality service provider and strategic partner, adjusting resources as needed, asking the right questions, and capably filling project knowledge gaps. IDC Health Insights assessed eight drug safety service providers for this report, which is designed to evaluate the characteristics of each firm.

In naming Accenture as a leader, the report’s author, Alan S. Louie, PhD, research director, of IDC Health Insights’ Life Science R&D Strategy and Technology research, said, "The drug safety services space within the life sciences industry has matured and is increasingly a mainstream contributor to helping to advance the industry forward. Unsustainable growth in drug safety BPO and evolving drug safety regulatory compliance requirements are forcing leading service providers in the space to continue to innovate, and IDC expects that leading service providers like Accenture in the space will be those vendors that continue to seek better and more efficient ways to deliver drug safety services looking forward."

Kevin Julian, a senior managing director leading the Accenture Life Sciences practice in North America said, "We believe Accenture’s positioning as a leader for a second time in this report is verification of the results we deliver every day to our life sciences’ clients who entrust us with drug safety services. We are focused on helping our clients pivot to the patient and improve patient safety by using innovative technologies to drive efficiency, help enable automation and advanced analytics, while maintaining quality and compliance.”

IDC Health Insights focuses on the following key criteria to define excellence in drug safety services:

The IDC MarketScape divides potential key strategy measures for success into two primary categories: capabilities and strategies. IDC Health Insights specifically noted in this report, “Building on an aggressive growth and acquisition strategy, Accenture has diversified significantly beyond its traditional big pharma focus and has grown its presence among emerging and mid-tier life science companies in recent years.”

This latest report follows an April 2017 IDC Perspective, “How Machine Learning and Cognitive Computing are Delivering Near-Term Value and ROI in Life Science R&D Today.” In this IDC Perspective, Accenture’s PV First - a cloud-based platform for pharmacovigilance - was cited: “With ongoing machine learning and continuing automation of new drug safety analytics insights, PV First should continue to mitigate the level of drug safety resources needed to maintain full drug safety regulatory compliance.”

About Accenture
Accenture is a leading global professional services company, providing a broad range of services and solutions in strategy, consulting, digital, technology and operations. Combining unmatched experience and specialized skills across more than 40 industries and all business functions – underpinned by the world’s largest delivery network – Accenture works at the intersection of business and technology to help clients improve their performance and create sustainable value for their stakeholders. With approximately 401,000 people serving clients in more than 120 countries, Accenture drives innovation to improve the way the world works and lives. Visit us at www.accenture.com.

About IDC MarketScape
IDC MarketScape vendor analysis model is designed to provide an overview of the competitive fitness of ICT (information and communications technology) suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective vendors.

1 IDC MarketScape: Worldwide Life Science Drug Safety Services 2017 Vendor Assessment, doc #US42595616 , June 2017.
2 How Machine Learning and Cognitive Computing are Delivering Near-Term Value and ROI in Life Science R&D Today, doc #US42491417, April 2017

# # #


Cam Granstra
+ 1 312 693 5992